Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 9

Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

October 28, 2024

James K. McCloskey, MD, John Theurer Cancer Center, Thomas W. LeBlanc, MD, MA

Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes.

EP. 1: Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP. 2: Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP. 3: Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP. 4: Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP. 5: First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP. 6: Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP. 7: Second-Line LR- MDS Setting: Treatment Options and Considerations

EP. 8: Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

Now Viewing

EP. 9: Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP. 10: First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP. 11: Imetelstat and IMerge Trial Review

EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

Video content above is prompted by the following:

What is the role of luspatercept in the RS-negative population? When do you consider it as first-line treatment in this particular patient population?

Resource link: COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).

Resource link: Platzbecker U, et al. Phase II PACE-MDS study. J Clin Oncol, 2022.

Resource link: Platzbecker U, et al. Comparative biomarkers by RS status COMMANDS trial. EHA 2024, abstract P763.

How do EPO levels factor into your treatment approach for this patient
Please comment on outcomes in the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024) based on EPO levels (<200).